Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JMEY-KL13
- Development stage
- Preclinical
- Lead developer
- Jianmin Pharmaceutical Group
01
Overview
JMEY-KL13 is an investigational drug candidate being developed by Jianmin Pharmaceutical Group for the treatment of atopic dermatitis. It is currently in the preclinical and CMC (Chemistry, Manufacturing, and Controls) stage of development. The drug is part of the company's pediatric pipeline, as indicated by the 'JMEY' prefix, which is managed through the Jianmin Pediatric Research Institute. While specific details regarding its molecular target, modality, and mechanism of action have not been publicly disclosed, the program represents Jianmin's effort to expand therapeutic options for inflammatory skin conditions in children.
Beyond the preview
Go deeper on JMEY-KL13.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JMEY-KL13.